USPTO serial 79229680
MERXIN
Reviewed by CopyMark Law Group
Reg. 5730393Status 739Registered
- Filing date
- Status date
- Registration date
- Apr 23, 2019
- Examiner
- COLLOPY, DIANE PATRICIA
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with MERXIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Coventry CV1 3PP, GB
Coventry CV1 3PP, GB
King's Lynn, Norfolk, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Geza C Ziegler Jr
Geza C Ziegler Jr ZIEGLER IP LAW GROUP LLC.2000 Post Road, Suite 205Fairfield, CT 06824United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Pharmaceuticals for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders adapted for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical compositions for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders adapted for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical preparations for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders for delivery into the body via the lungs or via the nasal passageway; Pharmaceutical preparations for inhalers, namely, medical pharmaceutical compositions for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders structured for delivery into the body by nebulizer, aerosol, or dry powder, via the lungs or via the nasal passageway; Dietary supplements; Pharmaceutical products for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for treating viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders ] | SECTION 7(e) - CANCELLED | — |
| 009 | [ Vials for scientific purposes being laboratory equipment; Vials for laboratory use; Glass tubes for scientific purposes being laboratory equipment ] * Laboratory equipment for scientific purposes, namely, vials * | SECTION 7(e) - CANCELLED | — |
| 010 | * medical inhalers that are sold empty and in bulk via business-to-business transactions through business-to-business channels of trade * [ [ Surgical, medical, dental and veterinary apparatus and instruments, namely, injection devices for administering drugs sold empty; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Medical syringes sold empty for administering pharmaceuticals; Medical apparatus for introducing pharmaceutical preparations into the human body; Inhalers for medical use; ] Medical inhalers * Sold Empty * [ ; Respiratory monitors for medical use; Apparatus for measuring lung function; Spirometers for examining the function of the lungs; Spirometers; Spirometer mouth pieces and tubing; breath gas analyzers for medical diagnostics; Replacement cartridges for medical inhalers sold empty; Nebulizer for administering medication in the form of a mist inhaled into the lungs, for treatment of asthma and respiratory diseases ] ] | ACTIVE | — |
| 042 | * design and development of medical inhalers sold empty and in bulk to third-party drug manufacturers and not for sale directly to end users * [ Scientific and technological services, namely, research and design in the field of drug delivery via the lungs or via the nasal passageway; Scientific and technological design of new products for others; Advisory services relating to [ design engineering ] * design of new products for others * ; Advisory services relating to [ product testing ] * testing of new products for others * ; Product design and development in the field of drug delivery via the lungs or via the nasal passageway; New product design services, namely, analysis and evaluation of product design; [ engineering design and consultancy ] * new product design and consultancy services * ; Professional consultancy relating to medical technology; [ engineering project management services, not for business purposes; Engineering research ] * project management services in the field of medical and pharmaceutical engineering, not for business purposes; Scientific research in the field of medical and pharmaceutical engineering * ; Pharmaceutical research and development services; research and development for the pharmaceutical industry; Research relating to medicines ] | ACTIVE | — |
| 044 | [ Pharmaceutical compounding services; Pharmaceutical compounding consultation services; Pharmaceutical compounding advisory services; Medical services; Veterinary services; Hygienic and beauty care for animals; Hygienic and beauty care for humans ] | SECTION 7(e) - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Merxin Ltd
- Other trademarks owned by Merxin Ltd
- Other trademarks owned by Merxin Ltd
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MERXIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 17, 2025 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Jul 17, 2025 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Jul 15, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 22, 2025 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Apr 17, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 17, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Apr 17, 2025 | EWOR | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | — |
| Apr 17, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 17, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 16, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 2, 2024 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Apr 23, 2024 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Apr 23, 2024 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Aug 24, 2023 | NCP7 | NOTICE OF PARTIAL CANCELLATION SEC. 7 SURRENDER EMAILED | — |
| Aug 23, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Aug 23, 2023 | C7P. | CANCELLED SEC. 7 - PARTIAL | — |
| Aug 22, 2023 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 15, 2023 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Apr 11, 2023 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Mar 7, 2023 | A7OK | AMENDMENT UNDER SECTION 7 - PROCESSED | — |
| Mar 6, 2023 | PLGL | ASSIGNED TO PARALEGAL | — |
| Feb 15, 2023 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Aug 23, 2022 | INNA | INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE | — |
| Jul 9, 2022 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jan 5, 2022 | A7OK | AMENDMENT UNDER SECTION 7 - PROCESSED | — |
| Jan 4, 2022 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Jan 3, 2022 | PRAM | POST REGISTRATION ACTION MAILED - SEC. 7 | — |
| Jan 3, 2022 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Nov 24, 2021 | WDRL | OTQR WITHDRAWAL FROM PUBLICATION | — |
| Oct 27, 2021 | NCP7 | NOTICE OF PARTIAL CANCELLATION SEC. 7 SURRENDER EMAILED | — |
| Oct 26, 2021 | XXXX | POST REGISTRATION ACTION CORRECTION | — |
| Oct 26, 2021 | C7P. | CANCELLED SEC. 7 - PARTIAL | — |
| Oct 22, 2021 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Oct 18, 2021 | PRAM | POST REGISTRATION ACTION MAILED - SEC. 7 | — |
| Oct 14, 2021 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 18, 2021 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| May 18, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 18, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 18, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| May 18, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 18, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 18, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 18, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 18, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 18, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| May 18, 2021 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| May 18, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 18, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 18, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 30, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 14, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 14, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 23, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jun 14, 2019 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Apr 23, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 5, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 5, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 2, 2019 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 16, 2019 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 16, 2019 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 16, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 28, 2018 | ALIE | ASSIGNED TO LIE | — |
| Dec 10, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 10, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 10, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 10, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 10, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 27, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 26, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 26, 2018 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jul 24, 2018 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 24, 2018 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 24, 2018 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 29, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 29, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 29, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 23, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 1, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 1, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 24, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 23, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 3, 2018 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Apr 29, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 28, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 27, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 10, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 6, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 5, 2018 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |